Evaluate Bioequivalence of Palonosetron (0.25mg/5mL)

Inclusion criteria

• . Healthy adult male or female subjects between 20-45 years of age (inclusive) at the screening visit.
• . Body mass index (BMI) between 18 and 27 kg/m2 (not inclusive) at the screening visit.
• . Acceptable medical history and physical examination including:
• . Acceptable biochemistry determinations (within normal limits or considered by the investigator or physician to be of no clinical significance) within two months prior to Period I dosing, which includes AST (SGOT), ALT (SGPT), γ-GT, alkaline phosphatase, total bilirubin, albumin, glucose, BUN, uric acid, creatinine, total cholesterol and triglyceride (TG).
• . Acceptable hematology (within normal limits or considered by the investigator or physician to be of no clinical significance) within two months prior to Period I dosing, which includes hemoglobin, hematocrit, red blood cell count, white blood cell count with differentials and platelets.
• . Acceptable urinalysis (within normal limits or considered by the investigator or physician to be of no clinical significance) within two months prior to Period I dosing, which includes pH, blood, glucose, ketones, bilirubin and protein.
• . Female of childbearing potential practicing an acceptable method of birth control for the duration of the study.
• . Have signed the written informed consent to participate in the study.

Exclusion criteria